These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 15251371)

  • 1. Deferred versus prophylactic therapy with gancyclovir for cytomegalovirus in allograft liver transplantation.
    Lianghui G; Shusen Z; Tingbo L; Yan S; Weilling W; Anwei L
    Transplant Proc; 2004 Jun; 36(5):1502-5. PubMed ID: 15251371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
    Ahsan N; Holman MJ; Yang HC
    Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
    Iberer F; Tscheliessnigg KH; Halwachs G; Auer T; Wasler A; Petutschnigg B; Müller H; Freigassner M; Allmayr T; Hipmair G
    Wien Klin Wochenschr; 1995; 107(23):718-22. PubMed ID: 8560893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and limitations of preemptive therapy against cytomegalovirus infections in heart transplant patients.
    Casillo R; Grimaldi M; Ragone E; Maiello C; Marra C; De Santo L; Amarelli C; Romano G; Della Corte A; Portella G; Tripodi MF; Fortunato R; Cotrufo M; Utili R
    Transplant Proc; 2004 Apr; 36(3):651-3. PubMed ID: 15110622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preemptive therapy with intravenous ganciclovir for the prevention of cytomegalovirus disease in lung transplant recipients.
    Monforte V; Román A; Gavaldà J; Bravo C; Gispert P; Pahissa A; Morell F
    Transplant Proc; 2005 Nov; 37(9):4039-42. PubMed ID: 16386621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ; Busuttil RW
    Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CMV hepatitis after liver transplantation: incidence, clinical course, and long-term follow-up.
    Seehofer D; Rayes N; Tullius SG; Schmidt CA; Neumann UP; Radke C; Settmacher U; Müller AR; Steinmüller T; Neuhaus P
    Liver Transpl; 2002 Dec; 8(12):1138-46. PubMed ID: 12474153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen.
    Thomas LD; Milstone AP; Miller GG; Loyd JE; Stephen Dummer J
    Clin Transplant; 2009; 23(4):476-83. PubMed ID: 19453645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [pp65 antigenemia in evaluation of cytomegalovirus infection after kidney transplantation].
    Orlić P; Dvornik S; Husnjak SC; Aralica M; Orlić L; Zivcić-Cosić S; Sladoje-Martinović B; Fućak M
    Acta Med Croatica; 2003; 57(1):49-52. PubMed ID: 12876863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience.
    Manteiga R; Martino R; Sureda A; Labeaga R; Brunet S; Sierra J; Rabella N
    Bone Marrow Transplant; 1998 Nov; 22(9):899-904. PubMed ID: 9827819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
    Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
    J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
    Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN
    Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M
    Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
    Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of CMV-DNA in peripheral blood leukocytes of liver transplant patients after ganciclovir treatment.
    Loginov R; Höckerstedt K; Lautenschlager I
    Arch Virol; 2003 Jul; 148(7):1269-74. PubMed ID: 12827460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus infection in renal transplant recipients.
    Carstens J; Andersen HK; Spencer E; Madsen M
    Transpl Infect Dis; 2006 Dec; 8(4):203-12. PubMed ID: 17116133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.
    Paya CV; Wilson JA; Espy MJ; Sia IG; DeBernardi MJ; Smith TF; Patel R; Jenkins G; Harmsen WS; Vanness DJ; Wiesner RH
    J Infect Dis; 2002 Apr; 185(7):854-60. PubMed ID: 11920308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients.
    Madan RP; Campbell AL; Shust GF; Kahn AR; Wistinghausen B; Posada R; Kerkar N; Shneider BL; Emre S; Herold BC
    Transplantation; 2009 May; 87(9):1318-24. PubMed ID: 19424031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
    Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T
    Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.